{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:27:40Z","timestamp":1778657260811,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013996","name":"Global Health Innovative Technology Fund","doi-asserted-by":"publisher","award":["GHIT-RFP-PD-2013-002"],"award-info":[{"award-number":["GHIT-RFP-PD-2013-002"]}],"id":[{"id":"10.13039\/501100013996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013996","name":"Global Health Innovative Technology Fund","doi-asserted-by":"publisher","award":["GHIT-RFP-PD-2017-001"],"award-info":[{"award-number":["GHIT-RFP-PD-2017-001"]}],"id":[{"id":"10.13039\/501100013996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013996","name":"Global Health Innovative Technology Fund","doi-asserted-by":"publisher","award":["E1224"],"award-info":[{"award-number":["E1224"]}],"id":[{"id":"10.13039\/501100013996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parasitology International"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.parint.2020.102278","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T10:24:47Z","timestamp":1608891887000},"page":"102278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases"],"prefix":"10.1016","volume":"81","author":[{"given":"Katsura","family":"Hata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parint.2020.102278_bb0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0924-8579(02)00273-X","article-title":"In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease","volume":"21","author":"Urbina","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.parint.2020.102278_bb0010","author":"Research & Development"},{"key":"10.1016\/j.parint.2020.102278_bb0015","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1046\/j.1365-2958.2003.03481.x","article-title":"Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly","volume":"48","author":"Tsukahara","year":"2003","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.parint.2020.102278_bb0020","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1128\/AAC.00366-11","article-title":"Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis","volume":"55","author":"Hata","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2020.102278_bb0025","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/AAC.00291-11","article-title":"In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds","volume":"55","author":"Miyazaki","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2020.102278_bb0030","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis","volume":"56","author":"Watanabe","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2020.102278_bb0035","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02319-17","article-title":"In vitro and in vivo evaluation of the antifungal activity of APX001A\/APX001 against Candida auris","volume":"62","author":"Hager","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2020.102278_bb0040","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01735-19","article-title":"Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary Scedosporiosis or disseminated Fusariosis","volume":"64","author":"Alkhazraji","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2020.102278_bb0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1248\/yakushi.15-00233-3","article-title":"Development and distribution of drugs for NTDs: efforts of one pharmaceutical company","volume":"136","author":"Asada","year":"2016","journal-title":"J. Pharmaceut. Soc. Jpn"},{"key":"10.1016\/j.parint.2020.102278_bb0050","author":"World Health Organization"},{"key":"10.1016\/j.parint.2020.102278_bb0055","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1128\/AAC.40.10.2237","article-title":"In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum","volume":"40","author":"Hata","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2020.102278_bb0060","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1128\/AAC.40.10.2243","article-title":"Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and Cryptococcosis","volume":"40","author":"Hata","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2020.102278_bb0065","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1128\/AAC.43.9.2236","article-title":"In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America","volume":"43","author":"SENTRY Participants Group","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2020.102278_bb0070","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1468-3083.2005.01212.x","article-title":"Ravuconazole Onychomycosis Group A phase I\/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis","volume":"19","author":"Gupta","year":"2005","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.parint.2020.102278_bb0075","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1016\/j.bmcl.2003.08.029","article-title":"Phosphonooxymethyl prodrugs of the broad Spectrum antifungal azole, Ravuconazole: synthesis and biological properties","volume":"13","author":"Ueda","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.parint.2020.102278_bb0080","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/1346-8138.14607","article-title":"Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: a multicenter, double-blind, randomized phase III study","volume":"45","author":"Watanabe","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.parint.2020.102278_bb0085","author":"World Health Organization"},{"key":"10.1016\/j.parint.2020.102278_bb0090","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1126\/science.273.5277.969","article-title":"Cure of short- and Long-term experimental Chagas\u2019 disease using D0870","volume":"273","author":"Urbina","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.parint.2020.102278_bb0095","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4269\/ajtmh.1986.35.280","article-title":"In vitro and in vivo effects of itraconazole against trypanosoma cruzi","volume":"35","author":"McCabe","year":"1986","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.parint.2020.102278_bb0100","doi-asserted-by":"crossref","first-page":"e00401","DOI":"10.1128\/AAC.00401-18","article-title":"Outcome of E1224-Benznidazole combination treatment for infection with a multidrug-resistant Trypanosoma cruzi strain in mice","volume":"62","author":"Diniz","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2020.102278_bb0105","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1473-3099(17)30538-8","article-title":"On behalf of the E1224 Study Group, Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial","volume":"18","author":"Torrico","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.parint.2020.102278_bb0110","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas\u2019 disease","volume":"370","author":"Molina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parint.2020.102278_bb0115","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/17460441.2019.1652593","article-title":"Advances in preclinical approaches to Chagas disease drug discovery","volume":"14","author":"Villalta","year":"2019","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.parint.2020.102278_bb0125","series-title":"Drugs for Neglected Diseases initiative","article-title":"The BENDITA study: a Phase II study to assess safety, tolerability, and efficacy of different benznidazole regimens, alone and in combination with fosravuconazole","year":"2019"},{"key":"10.1016\/j.parint.2020.102278_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002942","article-title":"Madurella mycetomatis Is Highly Susceptible to Ravuconazole","volume":"8","author":"Ahmed","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.parint.2020.102278_bb0135","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1128\/AAC.01170-12","article-title":"In vitro antifungal activity of isavuconazole against madurella mycetomatis","volume":"56","author":"Kloezen","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2020.102278_bb0140","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1128\/AAC.48.7.2742-2746.2004","article-title":"In vitro susceptibilities of madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5-[(Phenylamino)Carbonyl]-2H-Tetrazolium Hydroxide (XTT) assay","volume":"48","author":"Ahmed","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2020.102278_bb0145","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1128\/AAC.49.4.1364-1368.2005","volume":"49","author":"van de Sande","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2020.102278_bb0150","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1128\/AAC.01045-10","article-title":"In vitro susceptibility of madurella mycetomatis to posaconazole and terbinafine","volume":"55","author":"van Belkum","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2020.102278_bb0155","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1128\/AAC.01546-09","article-title":"Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents","volume":"54","author":"van de Sande","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2020.102278_bb0160","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/AAC.42.11.3018","article-title":"Organism-dependent fungicidal activities of azoles","volume":"42","author":"Manavathu","year":"1998","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Parasitology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383576920302282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383576920302282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:08:55Z","timestamp":1778623735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1383576920302282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":31,"alternative-id":["S1383576920302282"],"URL":"https:\/\/doi.org\/10.1016\/j.parint.2020.102278","relation":{},"ISSN":["1383-5769"],"issn-type":[{"value":"1383-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases","name":"articletitle","label":"Article Title"},{"value":"Parasitology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parint.2020.102278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102278"}}